We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-28.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$79.3M
AUM Growth
-$67.7M
(-46%)
Cap. Flow
-$24.1M
Cap. Flow
% of AUM
-30.41%
Top 10 Holdings %
Top 10 Hldgs %
54.45%
Holding
159
New
32
Increased
24
Reduced
41
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BGXX
Bright Green Corporation Common Stock
BGXX
|
+$7.36M |
| 2 |
Nuvectis Pharma
NVCT
|
+$5.9M |
| 3 |
BLRX
BioLineRX
BLRX
|
+$4.33M |
| 4 |
AKTX
Akari Therapeutics
AKTX
|
+$4.22M |
| 5 |
TBLT
ToughBuilt Industries, Inc. Common Stock
TBLT
|
+$1.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gevo
GEVO
|
+$15.3M |
| 2 |
BioVie
BIVI
|
+$1.26M |
| 3 |
PharmaCyte Biotech
PMCB
|
+$1.25M |
| 4 |
NEPT
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
|
+$1.05M |
| 5 |
MMAT
Meta Materials Inc. Common Stock
MMAT
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.68% |
| 2 | Technology | 5.89% |
| 3 | Consumer Discretionary | 4.32% |
| 4 | Industrials | 3.44% |
| 5 | Energy | 1.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $10.1M | 12.76% |
1,275
+989
| +346% | +$108K |
|
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $6.42M | 8.09% |
389
-836
| -68% | -$152K |
|
|
BGXX
3
DELISTED
Bright Green Corporation Common Stock
BGXX
| $5.14M | 6.49% |
+4,761,905
| New | +$7.36M |
|
|
4
Nuvectis Pharma
NVCT
$625M
| $4.49M | 5.66% |
+632,979
| New | +$5.9M |
|
|
BCTXW
5
PUT
DELISTED
BriaCell Therapeutics Corp Warrant
BCTXW
| $3.18M | 4.01% |
5,661
+660
| +13% | +$1.97K |
|
|
TCDA
6
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
| $3M | 3.79% |
2,863
+92
| +3% | +$1.01K |
|
7
Dogness International Corp
DOGZ
$14M
| $2.84M | 3.59% |
121,517
+16,764
| +16% | +$513K |
|
|
BLRX
8
BioLineRX
BLRX
$12.2M
| $2.81M | 3.54% |
+75,853
| New | +$4.33M |
|
|
AKTX
9
Akari Therapeutics
AKTX
$14.8M
| $2.58M | 3.26% |
+5,129
| New | +$4.22M |
|
10
PUT
Zevra Therapeutics
ZVRA
$575M
| $2.58M | 3.26% |
4,140
+310
| +8% | +$1.76K |
|
11
PUT
Actinium Pharmaceuticals
ATNM
$27.2M
| $1.58M | 2% |
2,143
+379
| +21% | +$2.36K |
|
|
12
Zevra Therapeutics
ZVRA
$575M
| $1.55M | 1.96% |
248,592
-45,895
| -16% | -$260K |
|
13
Cocrystal Pharma
COCP
$12.9M
| $1.54M | 1.94% |
440,355
-50,389
| -10% | -$236K |
|
|
14
PharmaCyte Biotech
PMCB
$6.33M
| $1.36M | 1.72% |
567,600
-493,811
| -47% | -$1.25M |
|
|
HCDIZ
15
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIZ
| $1.27M | 1.6% |
1,439,795
-287,974
| -17% | -$94.1K |
|
|
VRPX
16
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
| $1.25M | 1.58% |
4,218
-20
| -0.5% | -$7.2K |
|
|
AIOS
17
AIOS Tech
AIOS
$41.1M
| $1.13M | 1.43% |
10,885
-2,879
| -21% | -$431K |
|
18
Recon Technology
RCON
$39.6M
| $1.12M | 1.42% |
109,645
+5,260
| +5% | +$63.3K |
|
19
Pulmatrix
PULM
$6.14M
| $1.11M | 1.41% |
312,000
+60,242
| +24% | +$268K |
|
20
Onconetix
ONCO
$3.06M
| $944K | 1.19% |
3
-1
| -25% | -$438K |
|
|
MMAT
21
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $891K | 1.12% |
13,728
-11,945
| -47% | -$1.05M |
|
|
TBLT
22
DELISTED
ToughBuilt Industries, Inc. Common Stock
TBLT
| $887K | 1.12% |
+6,688
| New | +$1.69M |
|
|
TCDA
23
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
| $796K | 1% |
760
+152
| +25% | +$1.66K |
|
24
ReWalk Robotics
LFWD
$19.6M
| $782K | 0.99% |
10,482
-2,107
| -17% | -$174K |
|
|
CAN
25
Canaan Creative
CAN
$178M
| $730K | 0.92% |
222,559
-213,456
| -49% | -$779K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q3 2022 Portfolio in Review
As of Q3 2022, Sabby Management held 159 positions worth $79.3M, down 46% from $147M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Sabby Management withdrew a net $24.1M in Q3 2022, closing 43 positions and reducing 41 holdings. Its most notable exit was Gevo, an estimated $15.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 13% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Sabby Management opened a new position in Bright Green Corporation Common Stock worth $5.14M.
- Sabby Management's largest Q3 2022 buy was Bright Green Corporation Common Stock: 4,761,905 shares worth $5.14M.
- Sabby Management added most to Dogness International Corp in Q3 2022, an estimated $513K increase.
- Sabby Management's biggest Q3 2022 reduction was BioVie, cutting an estimated $1.26M.
- Sabby Management fully exited Gevo in Q3 2022, selling an estimated $15.3M.
- Sabby Management's ten largest holdings make up 54% of its $79.3M portfolio in Q3 2022.
- Sabby Management opened 32 new positions and closed 43 in Q3 2022.
- Sabby Management's portfolio value fell 46% quarter-over-quarter to $79.3M.
Based on Sabby Management's 13F filing for Q3 2022, filed 14 Nov 2022.